PRESENTASI

ANTIGEN
SAFARI WAHYU JATMIKO
Manna, P.R.; Gray, Z.C.; Reddy, P.H.
Healthy Immunity on Preventive
Medicine for Combating COVID-19.
Nutrients 2022, 14, 1004.
https://doi.org/10.3390/nu14051004
SEL T TIDAK BISA MENGENALI
ANTIGEN LANGSUNG

Zhong, J., Xu, J.-F., Yang, P., Liang, Y.,

& Wang, C.-Y. (2011). Innate
Immunity in the Recognition of β-
Cell Antigens in Type 1 Diabetes.
InTech. doi: 10.5772/22264
 PENGAMBILAN ANTIGEN

Pathak, C.; Vaidya, F.U.; Waghela, B.N.; Jaiswara, P.K.; Gupta, V.K.; Kumar, A.; Rajendran, B.K.; Ranjan, K. Insights of Endocytosis Signaling in Health and Disease. Int. J. Mol. Sci. 2023, 24, 2971.
https://doi.org/10.3390/ijms24032971
 ANTIGEN
PRESENTATION

Harryvan TJ, de Lange S, Hawinkels LJAC, Verdegaal EME. The ABCs

of Antigen Presentation by Stromal Non-Professional Antigen-
Presenting Cells. International Journal of Molecular Sciences. 2022;
23(1):137. https://doi.org/10.3390/ijms23010137
 STRUKTUR &
LOKASI MHC

Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg

S, Noé F and Freund C (2017) Major Histocompatibility Complex
(MHC) Class I and MHC Class II Proteins: Conformational Plasticity
in Antigen Presentation. Front. Immunol. 8:292. doi:
 PRESENTASI ANTIGEN
MELALUI MHC I

D’Amico S, Tempora P, Melaiu O, Lucarini V, Cifaldi L, Locatelli F

and Fruci D (2022) Targeting the antigen processing and
presentation pathway to overcome resistance to immune
checkpoint therapy. Front. Immunol. 13:948297. doi:
10.3389/fimmu.2022.948297
 PRESENTASI ANTIGEN
MELALUI MHC II

Ishina, I.A.; Zakharova, M.Y.; Kurbatskaia, I.N.; Mamedov, A.E.;

Belogurov, A.A., Jr.; Gabibov, A.G. MHC Class II Presentation in
Autoimmunity. Cells 2023, 12, 314.
https://doi.org/10.3390/cells12020314
PRESENTASI
SILANG

Embgenbroich M and Burgdorf S (2018) Current

Concepts of Antigen Cross-Presentation. Front.
Immunol. 9:1643. doi: 10.3389/fimmu.2018.01643
 PRESENTASI
SILANG
Couture A, Garnier A, Docagne F, Boyer O, Vivien D, Le-Mauff B, Latouche J-B and Toutirais O
(2019) HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy. Front.
Immunol. 10:1081. doi: 10.3389/fimmu.2019.01081
 NON PROFESSIONAL
ANTIGEN PRESENTING CELL

Boccasavia VL, Bovolenta ER, Villanueva A, Borroto A, Oeste

CL, van Santen HM, Prieto C, Alonso-López D, Diaz-Muñoz
MD, Batista FD, Alarcón B. Antigen presentation between T
cells drives Th17 polarization under conditions of limiting
antigen. Cell Rep. 2021 Mar 16;34(11):108861. doi:
10.1016/j.celrep.2021.108861.
 NON PROFESSIONAL
ANTIGEN PRESENTING CELL

Harryvan TJ, de Lange S, Hawinkels LJAC, Verdegaal EME. The ABCs

of Antigen Presentation by Stromal Non-Professional Antigen-
Presenting Cells. International Journal of Molecular Sciences. 2022;
23(1):137. https://doi.org/10.3390/ijms23010137
 NON PROFESSIONAL
ANTIGEN PRESENTING
CELL

Sano H, Imagawa A. Pancreatic β-cells express major histocompatibility complex class II: Do diabetic β-cells
have the capacity of antigen-presenting cells? J Diabetes Investig. 2020 Mar;11(2):281-283. doi:
10.1111/jdi.13155. Epub 2019 Nov 6. PMID: 31585494; PMCID: PMC7078092.
NON PROFESSIONAL ANTIGEN
PRESENTING CELL

Lin A and Loré K (2017) Granulocytes: New Members of

the Antigen-Presenting Cell Family. Front. Immunol.
8:1781. doi: 10.3389/fimmu.2017.01781
 NON PROFESSIONAL
ANTIGEN
PRESENTING CELL

Guo L, Shen S, Rowley JW, Tolley ND, Jia W, Manne BK, McComas KN, Bolingbroke B, Kosaka Y, Krauel K, Denorme F, Jacob SP, Eustes AS, Campbell RA, Middleton EA, He X, Brown SM, Morrell
CN, Weyrich AS, Rondina MT. Platelet MHC class I mediates CD8+ T-cell suppression during sepsis. Blood. 2021 Aug 5;138(5):401-416. doi: 10.1182/blood.2020008958. PMID: 33895821;
PMCID: PMC8343546.
NON PROFESSIONAL
ANTIGEN PRESENTING CELL

Marcoux G, Laroche A, Hasse S, Bellio M, Mbarik M, Tamagne M,

Allaeys I, Zufferey A, Lévesque T, Rebetz J, Karakeussian-Rimbaud A,
Turgeon J, Bourgoin SG, Hamzeh-Cognasse H, Cognasse F, Kapur R,
Semple JW, Hébert MJ, Pirenne F, Overkleeft HS, Florea BI, Dieude
M, Vingert B, Boilard E. Platelet EVs contain an active proteasome
involved in protein processing for antigen presentation via MHC-I
molecules. Blood. 2021 Dec 23;138(25):2607-2620. doi:
10.1182/blood.2020009957. PMID: 34293122.
 APC MIGRASI
KE
LIMFONODUS

King CA, Wegman AD and Endy TP (2020) Mobilization and Activation of the Innate Immune Response to Dengue Virus. Front. Cell. Infect. Microbiol. 10:574417. doi: 10.3389/fcimb.2020.574417
 APC MIGRASI KE
LIMFONODUS

Radtke AJ, Kastenmüller W, Espinosa DA, Gerner MY, Tse S-W, Sinnis P, et al. (2015
Lymph-Node Resident CD8α+ Dendritic Cells Capture Antigens from Migratory
Malaria Sporozoites and Induce CD8+ T Cell Responses. PLoS Pathog 11(2): e1004637
https://doi.org/10.1371/journal.ppat.1004637
 SEL T AKTIF

Baldin, A.V.; Savvateeva, L.V.; Bazhin, A.V.; Zamyatnin, A.A., Jr.

Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo
Loading or In Vivo Targeting. Cancers 2020, 12, 590.
https://doi.org/10.3390/cancers12030590
 SEL B AKTIF

Palm A-KE and Henry C (2019) Remembrance of Things Past:

Long-Term B Cell Memory After Infection and
Vaccination. Front. Immunol. 10:1787. doi:
10.3389/fimmu.2019.01787
  (1) Interference with CIITA transcription: EBV BZLF1 and
KSHV vIRF3 inhibit the CIITA promoter and subsequently
inhibit the transcription of MHC-II molecules.
 (2) Degradation of mRNA: HSV-1 UL41, EBV BGLF5 and
KSHV SOX can degrade the mRNA of CIITA and MHC-II
molecules.
 (3 and 4) Manipulation of HLA-DM and DR in ER: HCMV
US2, US3, pp65 and HSV-1 gB can associate with DM and/or
DR and impair the loading and presentation of MHC-II
peptides.
 (5) Manipulation of CD74: EBV BZLF1 can modulate CD74
post-translationally, interfering with the normal transport
and loading of peptides to MHC-II molecules.
 (6) Diversion to exosomes: HSV-1 gB associates with DR
after CD74 is released from DR, reducing the surface
expression of DR.
 (7) Manipulation of T cell receptor (TCR) recognition: EBV
gp42 can abolish the interactions between TCR on the CD4
T cell with MHC-II peptide complexes

IMUNOEVASI
Zuo, J.; Rowe, M. Herpesviruses Placating the Unwilling Host: Manipulation of the MHC Class II Antigen Presentation Pathway. Viruses 2012, 4, 1335-1353. https://doi.org/10.3390/v4081335
PEMANFAATAN PRESENTASI
ANTIGEN UNTUK TERAPI

Salah A, Wang H, Li Y, Ji M, Ou W-B, Qi N and Wu Y (2021) Insights

Into Dendritic Cells in Cancer Immunotherapy: From Bench to
Clinical Applications. Front. Cell Dev. Biol. 9:686544. doi:
10.3389/fcell.2021.686544
 PEMANFAATAN PRESENTASI ANTIGEN
UNTUK TERAPI

Couture A, Garnier A, Docagne F, Boyer O, Vivien D, Le-Mauff B, Latouche J-B and Toutirais O (2019) HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy. Front.
Immunol. 10:1081. doi: 10.3389/fimmu.2019.01081
TERIMA KASIH